Search Results - "Rubin, J.L"

PUK24 USE OF BIOMARKERS IN PROPENSITY SCORE MATCHING TO MITIGATE CHANNELING BIAS IN A RETROSPECTIVE COHORT OF ESRD PATIENTS by Wilson, S.M, Rubin, J.L

Get full text

PUK32 Lower Case Mix Adjusters are Associated with Lower Erythropoiesis-Stimulating Agent (ESA) and Other Bundled Costs by Sibbel, S.P, Rubin, J.L, Yang, A

Get full text

PUK16 Reduced Use of Erythropoiesis-Stimulating Agents and Intravenous Iron with Use of the Phosphate Binder Ferric Citrate: a Facility-Level Cost-Offset Model Under the Medicare Bundle by Mutell, R, Rubin, J.L, Bond, T.C, Mayne, T

Get full text

PUK30 Once Monthly Erythropoiesis Stimulating Agent (ESA) Dosing May Reduce ESA Utilization Compared to Thrice-Weekly ESA Dosing by Bond, T.C, Rubin, J.L, Wang, X, Yang, A

Get full text

PUK15 a Managed Care Cost-Offset Model for Ferric Citrate, an Experimental Phosphate Binder That Can Reduce the Use of Erythropoiesis-Stimulating Agents and Intravenous Iron in Hemodialysis Patients with Hyperphosphatemia by Mutell, R, Rubin, J.L, Bond, T.C, Mayne, T

Get full text

PUK29 Erythropoietin-Stimulating Agent (ESA) Dose Recovery Following Hospitalization of End Stage Renal Disease (ESRD) Patients by Wang, X, Bond, T.C, Rubin, J.L, Yang, A

Get full text

DM1 IMPACT OF A PHARMACY REFILL MANAGEMENT SYSTEM ON OUTCOMES IN END STAGE RENAL DISEASE (ESRD) PATIENTS by Rubin, J.L, Wilson, S.M, Golomb, J

Get full text

PUK1 INCIDENCE AND 30-DAY MORTALITY OF COMMUNITY ACQUIRED PNEUMONIA (CAP) IN THE MEDICARE FEE-FOR-SERVICE (FFS) POPULATION by Rubin, J.L, Li, S, Yu, H, Dunning, S, Sato, R

Get full text

PRO13 LIMITATIONS OF COST-EFFECTIVENESS METHODS WHEN ANALYZING LIFE-EXTENDING TREATMENTS FOR RARE, CHRONIC, GENETIC DISEASES: A CYSTIC FIBROSIS CASE STUDY by Lopez, A., Rubin, J.L., Chandler, C., Jena, A.B.

Get full text

PMU46 Impact of Assumptions Used in Cost-Effectiveness Analysis (CEA) on the Outcomes of CEA across Disease Areas by Holmes, H., Mahon, J., McGarry, L., Bromilow, T., Thorat, T., Wood, H., Rubin, J.L.

Get full text

PRS31 Modelling Survival of People with Cystic Fibrosis (PWCF) Aged ≥12 YEARS Homozygous for the F508DEL Mutation Treated with Ivacaftor/Tezacaftor/Elexacaftor and Ivacaftor (IVA/TEZ/ELX) by Vega-Hernandez, G., MacGregor, G., Lopez, A., Daly, C., Rubin, J.L.

Get full text

PRS2 Modelling Survival of People with Cystic Fibrosis (PWCF) Aged ≥12 YEARS Heterozygous for the F508DEL Mutation with a Minimal Function Mutation Treated with Ivacaftor/Tezacaftor/Elexacaftor and Ivacaftor (IVA/TEZ/ELX) by Vega-Hernandez, G., MacGregor, G., Lopez, A., Daly, C., Rubin, J.L.

Get full text

191 Lung function and health care resource utilization in patients with cystic fibrosis by Rubin-Cahill, J.L, Thayer, S, Watkins, A, Wagener, J, Hodgkins, P, Schechter, M.S

“…Objectives To investigate the association between FEV1 and annual health care resource utilization (HCRU) in patients diagnosed with cystic fibrosis (CF)…”
Get full text

190 Frequency and costs of pulmonary exacerbations and association with % predicted FEV1 in patients with cystic fibrosis by Rubin-Cahill, J.L, Thayer, S, Watkins, A, Wagener, J, Hodgkins, P, Schechter, M.S

“…Objectives To investigate the frequency and costs of pulmonary exacerbations (PEx) and the association between FEV1 and PEx in patients (pts) with cystic…”
Get full text

MS1 VALIDATION OF MODELED 5-YEAR SURVIVAL OUTCOMES AMONG PATIENTS WITH CYSTIC FIBROSIS (CF) TREATED WITH THE CF TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATOR (CFTRM) IVACAFTOR USING US CF FOUNDATION PATIENT REGISTRY (USCFFPR) DATA by Mcgarry, L., Lopez, A., Chandler, C., Pelligra, C., Alkhateeb, Z., Rubin, J.L., Liou, T.

Get full text

PRO117 ACCESS TO ORPHAN DRUGS IN THE UNITED KINGDOM: A REVIEW OF NICE DECISIONS FROM 2017-2018 by Thorat, T., Sliman, R.C., Farinella, M., Vega, G., Jao, R., Kumar, J., Rubin, J.L.

Get full text

PRO26 HEALTH CARE RESOURCE USE AND OUTCOMES AMONG INFANTS AND CHILDREN AGED <6 YEARS WITH CYSTIC FIBROSIS IN THE UNITED STATES by Hassan, M., Thorat, T., Bonafede, M., Limone, B., McGarry, L., Rubin, J.L.

Get full text

P067 Hospitalisations among children with cystic fibrosis aged <6 years by Thorat, T., Hassan, M., Bonafede, M., Limone, B., McGarry, L., Rubin, J.L.

Get full text

Atypical presentation of Henoch-Schonlein purpura: Case report and review of the literature by Rubin, J.L., Moy, J.

“…Henoch-Schonlein purpura (HSP) is a systemic vasculitis primarily affecting children, characterized by nonthrombocytopenic purpura and may include joint,…”
Get full text

190 Frequency and costs of pulmonary exacerbations and association with % predicted FEV 1 in patients with cystic fibrosis by Rubin-Cahill, J.L., Thayer, S., Watkins, A., Wagener, J., Hodgkins, P., Schechter, M.S.

Get full text